Clinical Trial

The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory

Completed
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to is to examine the impact of new RSV prevention medicines on the burden of RSV disease among young children. The main question it aims to answer is: What was the impact of the 2025 RSV prevention program on RSV-related hospitalisation in children under 2 years of age? Participants won't need to do anything additional for the study as only routinely collected health information will be used to answer the research question.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-04.
Status change: Not Yet Recruiting → Completed 2026-03-03
Trial Details
NCT Number NCT07164430
Lead Sponsor Nicola Irwin
Collaborators: Kirby Institute, The University of New South Wales
Conditions Respiratory Syncytial Virus (RSV) Infection, Respiratory Syncytial Virus Hospitalizations, Respiratory Syncytial Virus Immunization
Enrollment 2,792 participants
Start Date 2025-09-22
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-05